Search Results

Сontemporary art collage of human hands holding french fries or chips. Modern design. Copy space for ad.

Pharma Has Kept M&A Spending Small This Year, With Just One Deal Topping $5B

By far, the largest acquisition of 2024 was Novo Holdings’ yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion. Outside of that, the leading pharmaceutical companies kept to less than $5 billion per deal.

December 11, 2024

·

4 min read

·

Annalee Armstrong

Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration

Deals

Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff

Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.

January 22, 2025

·

5 min read

·

Annalee Armstrong

Press Releases

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

December 16, 2024

·

3 min read

Press Releases

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

December 12, 2024

·

4 min read

Blue DNA molecule helix with red human heart. Hereditary heart diseases, diagnosis of genetic diseases concept. Gene editing, biotechnology engineering. Low poly style Wireframe light structure Vector

Gene therapy

5 Cardio Gene Therapies on the Near Horizon

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic for cardiovascular diseases including congestive heart failure, chronic refractory angina and cardiomyopathy.

January 13, 2025

·

9 min read

·

Tristan Manalac

Staying ahead of your competitors. Accelerated development of the company. Innovation vision. Customized solution. Unique skills. Red paper plane and whites. 3d render

FDA

5 Novel FDA Approvals Notched in 2024

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming particularly in the oncology and neurosciences spaces.

January 13, 2025

·

7 min read

·

Heather McKenzie

FDA signage at its headquarters in Maryland

Regulatory

5 FDA Decisions to Watch in Q1

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy for hemophilia A and B.

January 6, 2025

·

8 min read

·

Tristan Manalac

Businessman makes employee cuts as part of layoff

Layoffs

The 5 Largest Biopharma Layoffs of 2024

While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even thousands of employees in 2024.

December 19, 2024

·

7 min read

·

Angela Gabriel

Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .

Neuroscience

5 Clinical Assets That Flopped in 2024

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five clinical trial flops that stole headlines over the past 12 months.

December 16, 2024

·

6 min read

·

Heather McKenzie

Update: AbbVie headquarters building in California

Neuropsychiatric disorders

AbbVie Absorbs $3.5B Cost of Schizophrenia Flop

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage trials. Tavapadon, meanwhile, has been a more rewarding asset for the pharma, clearing three Phase III Parkinson’s studies in 2024.

January 13, 2025

·

2 min read

·

Tristan Manalac